Baxter Selects BioCARE as Exclusive Distributor for OBIZUR

Baxter Selects BioCARE as Exclusive Distributor for OBIZUR

BioCARE has been selected by Baxter as the exclusive, national authorized distributor for OBIZUR, the only recombinant porcine sequence factor VIII replacement treatment for acquired hemophilia A (AHA). OBIZUR was approved by the FDA for the treatment of bleeding episodes in adults with AHA, a very rare and potentially life-threatening acute bleeding disorder.

Linda Matthews, president of BioCARE, said, “We appreciate Baxter’s confidence in our organization and our customer- and patient-focused approach. Our unique high-touch service model has earned BioCARE a reputation among manufacturers, hospitals, treatment centers, physicians, and patients for integrity, reliability and innovation. This is an important relationship for the treatment of AHA.”

OBIZUR is offered in single-use vials that are available in 10-vial, 5- vial and 1-vial packages and is for intravenous injection after reconstitution.

For more information about the efficacy and safety of OBIZUR, click OBIZUR_PI